Xarelto Sales Data
||Current sales rank, all
Last updated: February 2014 (updated quarterly).
The following data shows Xarelto U.S. retail sales in Q4 2013 compared to previous quarters.
* Units refer to the number of packages sold.
|June 28, 2013||FDA Issues Complete Response Letter for Xarelto (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome|
|June 20, 2013||FDA Sends Letter to J&J Over Xarelto DTC Ad|
|July 9, 2012||U.S. FDA Grants Priority Review for Xarelto (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE|
|January 9, 2012||NICE Needs More Evidence on New Treatment for People with Common Heart Condition|
|November 13, 2011||Blood Thinner Xarelto Shows Promise for Heart Patients|
|November 4, 2011||Xarelto Approved to Prevent Stroke in People With Abnormal Heartbeat|
|September 8, 2011||FDA Advisers Review Clot Drug|
|August 29, 2011||Ahead of the Bell: Blood Thinner Study Impresses|
|August 10, 2011||Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat|
|July 24, 2011||Anti-Clotting Drug May Cause Severe Bleeding With No Benefit|
|December 4, 2010||New Blood Thinner May Help Fight Dangerous Leg Clots|